JP2021532167A - 膵炎を治療するための組成物及び方法 - Google Patents

膵炎を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2021532167A
JP2021532167A JP2021518029A JP2021518029A JP2021532167A JP 2021532167 A JP2021532167 A JP 2021532167A JP 2021518029 A JP2021518029 A JP 2021518029A JP 2021518029 A JP2021518029 A JP 2021518029A JP 2021532167 A JP2021532167 A JP 2021532167A
Authority
JP
Japan
Prior art keywords
pcsk9
pcsk9 inhibitor
use according
pancreatitis
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532167A5 (https=
JPWO2019236528A5 (https=
Inventor
マイヤーズ，チャールズ，ディー．
ハバード，ブライアン，ケー．
セラーノ−ウー，マイケル，エイチ．
Original Assignee
アンジ ファーマ（ユーエス）エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジ ファーマ（ユーエス）エルエルシー filed Critical アンジ ファーマ（ユーエス）エルエルシー
Publication of JP2021532167A publication Critical patent/JP2021532167A/ja
Publication of JP2021532167A5 publication Critical patent/JP2021532167A5/ja
Publication of JPWO2019236528A5 publication Critical patent/JPWO2019236528A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C12Y304/11001—Leucyl aminopeptidase (3.4.11.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021518029A 2018-06-05 2019-06-04 膵炎を治療するための組成物及び方法 Pending JP2021532167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680896P 2018-06-05 2018-06-05
US62/680,896 2018-06-05
PCT/US2019/035310 WO2019236528A1 (en) 2018-06-05 2019-06-04 Compositions and methods for treating pancreatitis

Publications (3)

Publication Number Publication Date
JP2021532167A true JP2021532167A (ja) 2021-11-25
JP2021532167A5 JP2021532167A5 (https=) 2022-05-30
JPWO2019236528A5 JPWO2019236528A5 (https=) 2022-05-30

Family

ID=68770590

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518029A Pending JP2021532167A (ja) 2018-06-05 2019-06-04 膵炎を治療するための組成物及び方法

Country Status (9)

Country Link
US (1) US11679146B2 (https=)
EP (1) EP3801620A4 (https=)
JP (1) JP2021532167A (https=)
CN (1) CN112512574A (https=)
AU (1) AU2019282132A1 (https=)
CA (1) CA3102032A1 (https=)
MX (1) MX2020013155A (https=)
TW (1) TW202015727A (https=)
WO (1) WO2019236528A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
WO2022002160A1 (zh) * 2020-07-01 2022-01-06 陈敏 Pcsk9抑制剂在制备治疗多种疾病产品中的应用
CN114250194B (zh) * 2021-11-30 2023-04-11 四川大学华西医院 一种急性胰腺炎细胞模型的构建方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
CN107468687A (zh) * 2017-09-05 2017-12-15 吴蕾 黄连素作为细胞m3受体抑制剂的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856487A (en) 1996-02-14 1999-01-05 National Institute Of Immunology Application of protoberberine alkaloid, berberine, an immunosuppressive agent
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CN101467999A (zh) 2007-12-25 2009-07-01 郑州后羿制药有限公司 一种盐酸小檗碱复方制剂
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
CN101829113B (zh) 2009-07-14 2012-12-12 武汉大学 黄连素在治疗或预防流感病毒药物中的应用
AU2010298249A1 (en) 2009-09-23 2012-04-19 Carolus Therapeutics, Inc. Methods of treating inflammation
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
CN104815316A (zh) 2015-05-25 2015-08-05 苗怡文 一种治疗急慢性胰腺炎的中药制剂及其制备方法
US20190365656A1 (en) 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150140005A1 (en) * 2012-05-17 2015-05-21 Cyon Therapeutics Inc. Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
CN107468687A (zh) * 2017-09-05 2017-12-15 吴蕾 黄连素作为细胞m3受体抑制剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROG. LIPID RES., vol. 56, JPN6023020985, 2014, pages 47 - 66, ISSN: 0005255024 *

Also Published As

Publication number Publication date
US11679146B2 (en) 2023-06-20
MX2020013155A (es) 2021-04-29
US20210213111A1 (en) 2021-07-15
EP3801620A1 (en) 2021-04-14
CA3102032A1 (en) 2019-12-12
AU2019282132A8 (en) 2023-05-25
CN112512574A (zh) 2021-03-16
WO2019236528A1 (en) 2019-12-12
EP3801620A4 (en) 2022-04-20
TW202015727A (zh) 2020-05-01
AU2019282132A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
Padda et al. Small interfering RNA (siRNA) therapy
EP3010539B1 (en) Methods for treating nasal polyposis by administering an il-4r antagonist
JP2021532167A (ja) 膵炎を治療するための組成物及び方法
CA2967602C (en) METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
CN103740713A (zh) 补体拮抗剂及其应用
US9534219B2 (en) Methods of treating vascular inflammatory disorders
WO2013170367A1 (en) Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
Chen et al. A review of PCSK9 inhibitors and their effects on cardiovascular diseases
CN116617390A (zh) Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
Lopez-Pascual et al. FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis
CN120505318B (zh) LSR、LncRNA-LSR-AS1或靶向siRNA在预防和/或治疗高脂血症或其相关疾病中的应用
JP7216122B2 (ja) Ｉｌ－４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
Yu et al. Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown
KR102747096B1 (ko) 심한 변비를 치료하기 위한 조성물 및 방법
KR102930473B1 (ko) Gas5 억제제 및 smarca4 억제제를 유효성분으로 포함하는 간암 예방 또는 치료용 약학 조성물
ES2747630T3 (es) Métodos de tratamiento de poliposis nasal administrando un antagonista de IL-4R
Tomkin et al. Investigational therapies for hypercholesterolemia
Elrggal et al. Diabesity and the Kidney
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법
Kang et al. Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration
Xiang et al. Curcumin attenuates pressure overload-induced cardiac fibrosis in mice via modulating the miR-29b/HDAC4 axis
CN120693405A (zh) 降低一级预防受试者中重大不良心血管事件风险的方法
CN118599000A (zh) Lrp5作为靶向分子在治疗糖尿病肾病中的应用
HK40023224B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
JP2023521347A (ja) アンジオポエチン様３（ａｎｇｐｔｌ３）をサイレンシングするための遺伝子構築物及びその使用

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206